QSAM BIOSCI. DL-,0001
Share · US74738N2027 · A3DJED (XNCM)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of QSAM BIOSCI. DL-,0001
No Price
Company Profile for QSAM BIOSCI. DL-,0001 Share
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
Company Data
Name QSAM BIOSCI. DL-,0001
Company QSAM Biosciences, Inc.
Website
https://qsambio.com
Primary Exchange 
Frankfurt
Frankfurt
WKN A3DJED
ISIN US74738N2027
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Douglas R. Baum
Country United States of America
Currency EUR
Employees 0,0 T
Address Plaza 1, 78759 Austin
IPO Date 2012-08-13
Stock Splits
| Date | Split |
|---|---|
| 02.05.2024 | 1:2000 |
| 10.03.2022 | 1:40 |
| 10.09.2020 | 1:25 |
| 05.08.2015 | 1:7 |
| 18.03.2013 | 1:2 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | QSAM |
More Shares
Investors who hold QSAM BIOSCI. DL-,0001 also have the following shares in their portfolio:
